Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung...

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Genetic mutations in tumor cells create unique metabolic phenotypes essential for cancer cell proliferation.
• Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase are common in lung adenocarcinoma (LAD) and lead to oncogenic addiction.
• The precise relationship between mutated EGFR signaling and cancer cell metabolism remains unclear.

Purpose of the Study:

• To investigate the role of EGFR signaling in regulating aerobic glycolysis and other metabolic pathways in EGFR-mutated LAD cells.
• To elucidate the molecular mechanisms by which EGFR signaling influences cancer cell metabolism.
• To explore the potential of targeting metabolic pathways for improved therapeutic strategies in EGFR-mutated LAD.

Main Methods:

• Treatment of EGFR-mutated LAD cells with EGFR-tyrosine kinase inhibitors (TKIs).
• Measurement of metabolic parameters including lactate production, glucose consumption, and extracellular acidification rate (ECAR).
• Comprehensive metabolomic analysis to identify changes in key metabolic pathways (glycolysis, pentose phosphate pathway, pyrimidine biosynthesis, redox metabolism).
• Assessment of glucose transporter 3 (GLUT3) and carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) expression and activity.

Main Results:

• EGFR-TKIs significantly decreased lactate production, glucose consumption, and ECAR, confirming EGFR signaling's role in maintaining aerobic glycolysis.
• Metabolomic analysis revealed reduced levels of key metabolites in glycolysis, pentose phosphate pathway, pyrimidine biosynthesis, and redox metabolism following TKI treatment.
• Downregulation of glucose transporter 3 (GLUT3) was observed in TKI-sensitive LAD cells.
• EGFR signaling was found to activate the CAD enzyme, a crucial step in de novo pyrimidine synthesis.

Conclusions:

• EGFR signaling is a key regulator of global metabolic pathways, including aerobic glycolysis and pyrimidine biosynthesis, in EGFR-mutated LAD cells.
• The findings link therapeutic response to EGFR-TKIs with the modulation of cancer cell metabolism.
• Targeting these EGFR-regulated metabolic pathways presents a promising strategy for developing more effective therapies for patients with EGFR-mutated LAD.